• Patients
  • News
  • Construction commences on world-class GenesisCare cancer centre and research hub in Surrey
banner_fullwidth

Construction commences on world-class GenesisCare cancer centre and research hub in Surrey

  • Cancer patients across South East England to benefit from innovative adaptive treatment technologies and global oncology expertise

London, U.K. – Cancer patients from across South East England will soon have increased access to highly advanced oncology treatments and global clinical trials, with construction commencing on a new £30.5m cancer centre in Guildford, Surrey, set to open in 2023. 

The new cancer centre and research hub is the result of a partnership between GenesisCare and the Royal Surrey NHS Foundation Trust. It will provide patients with access to the latest treatment options for cancer, including highly targeted radiotherapy using a Magnetic Resonance Image Linear Accelerator (MR Linac). 

This exciting technology is not widely available in the UK but has been shown to improve outcomes for tumours that are moving or difficult to reach1. GenesisCare has used this advanced technology to successfully treat renal, pancreatic, and lung tumours at its Oxford centre, where surgery is not possible due to the complexity of the cancer.

Compared to conventional radiotherapy, treatment can be administered with greater sparing of normal tissues, over a shorter of period of time, resulting in fewer sessions and less disruption for patients.

In addition to offering highly advanced treatments, GenesisCare and the Royal Surrey NHS Foundation Trust will also partner on a comprehensive research and education program, including sharing best practices, training and development of NHS staff, as well as the participation in academic research and trials.  

Justin Hely, UK General Manager at GenesisCare, comments: “We are extremely proud to be extending our partnership with Royal Surrey Hospital, a recognised centre of excellence for cancer. Our new facility will offer innovative new treatments, novel therapies and clinical trials proven to deliver improved patient outcomes to cancer patients across the South East of England.

“Our collaboration with the Trust brings added benefits to both organisations and the patients we treat and enables us to provide patients with access to new treatment options in what will be an outstanding facility.”  

Louise Stead, Chief Executive at Royal Surrey NHS Foundation Trust, comments, “The partnership with GenesisCare via the establishment of the new centre at the Royal Surrey NHS Trust is a further step forward in our ambition to provide patients with the best care possible. Alongside access to world-class technology, the facility will enable our team to establish new dedicated training programmes that will expand the hospital’s expertise amongst a wider number of clinicians, helping to benefit more patients.”

The new centre will offer an integrated approach to cancer care, providing patients with access to seamless, personalised care so they feel supported throughout all stages of their treatment journey. Patients will have the opportunity to participate in exercise medicine, which is proven to improve patient outcomes, as well as a wellbeing program, including support groups, self-care treatments, dietary support, and wellbeing therapies, in partnership with charity Penny Brohn UK.

The facility is expected to open its doors to patients in the autumn of 2023. 

/content/dam/asset-migration/centres-and-staff/uk-centres-and-staff/UK_Oncology_Centre_Imagery_GA_Surrey_2.jpg

Justin Hely – General Manager UK, GenesisCare
Joe Mills – Director of Strategy, Royal Surrey NHS Foundation Trust
Ross Dunworth – Deputy CEO, Royal Surrey NHS Foundation Trust
Louise Stead – CEO, Royal Surrey NHS Foundation Trust
Richard Briggs – Head of Finance - Europe, GenesisCare
Dr Sharadah Essapen – Oncologist
Dr Carla Perna – Oncologist

-Ends-

References

1. Otazo, R., Lambin, P., Pignol, J., Ladd, M., Schlemmer, H., Baumann, M. and Hricak, H., 2021. MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. Radiology, 298(2), pp.248-260. (Otazo et al., 2021)